Candidate Vaccine Virus
Candidate Vaccine Virus - Related Videos
01:27
Development of Candidate Vaccine Viruses for Influenza Using Reverse Genetic Technology
0 Views •
2026
Begin with a mixture of eight plasmids to generate a candidate vaccine virus (CVV), a prototype influenza virus used in vaccine production.Each plasmid carries a complementary DNA (cDNA) copy encoding one gene segment of the influenza virus’s segmented genome.Six plasmids encode internal genes, and two encode antigen genes engineered to reduce viral pathogenicity.Add the plasmid mixture to a suspension of mammalian epithelial cells.Deliver a short electric pulse to induce temporary membrane...
06:17
Expression and Purification of Virus-like Particles for Vaccination
0 Views •
Cited by 28 •
2016
Here, we present a protocol for synthesizing virus-like particles using either baculovirus or mammalian expression systems, and ultracentrifugation purification. This highly customizable approach is used to identify viral antigens as vaccine targets in a safe and flexible manner.
02:58
Generating Recombinant Live-Attenuated Influenza Viruses for Vaccines
0 Views •
2025
The video showcases a method to create cold-adapted recombinant influenza viruses. It involves transfecting human cells with bi-directional plasmids, followed by incubation at lower temperature incubation to yield viruses suitable for vaccine production, characterized by reduced replication in warmer conditions.
09:04
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
0 Views •
Cited by 5 •
2020
Here we describe an indirect ELISA sandwich immunocapture to determine the immunogenic glycoprotein contents in rabies vaccines. This test uses a neutralizing Monoclonal Antibody (mAb-D1) recognizing glycoprotein trimers. It is an alternative to the in vivo NIH test to follow the consistency of vaccine potency during production.
10:16
Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes
0 Views •
Cited by 3 •
2019
Here, we present a protocol to produce an oral vaccine candidate against Type 1 diabetes in an edible plant.
FAQs
Its design presents pathogen-specific antigens to the immune system while reducing disease risk through weakening, inactivation, or other modification. Immune cells recognize these antigens and respond by producing antibodies and activating T cells. The resulting immune memory can prepare the body to respond more effectively when it encounters the target pathogen.
Antigen display determines whether immune cells can recognize features associated with the target pathogen. A suitable candidate presents pathogen-specific antigens strongly enough to activate antibody and T-cell responses, while its altered properties help minimize disease risk. This balance is central to judging whether the virus can support protective immunity.
These approaches alter the virus in different ways while preserving its ability to present relevant antigens. Weakening reduces its disease-causing potential, inactivation prevents the virus from remaining active, and modification can change its properties or enable antigen display. Comparing these designs helps researchers evaluate how viral form influences safety and immune activation.
Researchers examine both antibody and T-cell responses because the candidate must activate more than one arm of adaptive immunity. Antibodies reflect recognition of displayed pathogen-specific antigens, whereas T-cell activation provides another measure of immune engagement. Together, these outcomes help indicate whether the design is generating the protective response sought during development.
Laboratory studies assess safety, replication, immune activation, and protective efficacy. These evaluations help determine whether the virus behaves as intended, stimulates relevant immune responses, and provides evidence of protection against the target pathogen. Findings from this stage support decisions about whether a candidate is sufficiently promising for further development and eventual clinical evaluation.
Researchers can compare different candidate designs by examining their safety profiles, replication characteristics, immune activation, and protective efficacy in laboratory testing. They can also evaluate formulations to identify combinations that produce more suitable outcomes. This comparative approach helps prioritize vaccine strategies and guides the advancement of prevention methods for viral infections.